2025-11-07
minor
Study Status, Arms and Interventions, Outcome Measures v30
InterventionsAllogeneic Hematopoietic Stem Cell Transplantation (Procedure), Biospecimen Collection (Procedure), Bone Marrow Aspiration (Procedure)…→Allogeneic Hematopoietic Stem Cell Transplantation (Procedure), Biospecimen Collection (Procedure), Bone Marrow Aspiration (Procedure)…
Secondary endpoints8 entries, revised
Cumulative incidence of relapseRelapse
Show 27 earlier versions
2024-08-26
minor
Study Status, Study Description, Arms and Interventions v27
InterventionsAllogeneic Hematopoietic Stem Cell Transplantation (Procedure), Cyclophosphamide (Drug), Cyclosporine (Drug), Filgrastim (Biological)…→Allogeneic Hematopoietic Stem Cell Transplantation (Procedure), Biospecimen Collection (Procedure), Bone Marrow Aspiration (Procedure)…
Study description+361 characters
[...] lute neutrophil count is > 1,000/uL for 3 consecutive days.
Additionally, patients undergo bone marrow aspiration and biopsy, and echocardiography at baseline and blood sample collection and computed tomography (CT) or positron emission tomography (PET)/CT on study.
ARM B (LOW DOSE TREOSULFAN): Patients receive low dose treos [...] sodium or mycophenolate mofetil, and filgrastim as in Arm A. Additionally, patients undergo bone marrow aspiration and biopsy, and echocardiography at baseline and blood sample collection and CT or PET/CT on study.
After completion of transplant, patients are followed up a [...]
2024-05-21
minor
Study Status v26
Re-verified, no change to tracked fields
2023-11-21
minor
Study Status v25
Primary completion date2023-12-31→2024-12-31
Completion date2025-12-31→2026-12-31
2023-05-12
minor
2 amendments v23-v24
2 re-verifications since 2023-04-21, no change to tracked fields
2022-10-26
minor
Study Status, Eligibility v22
Eligibility criteria+22 characters
[...] 5% of detectable blasts in bone marrow specimen, evaluated noper earlierstandard thanof one month before conditioning regimen startcare.
Patients with documented CR but without hematologic recove [...] erformed and verified by an apheresis nurse prior to arrival at the Seattle Cancer Care Alliance (SCCA).
DONOR: Donor must meet selection criteria as defined by the [...] be screened for anti-DSA pre-transplant.
Patients with DSA mean fluorescent intensity (MFI) < 5000 after desensitization treatment, will be reviewedconsidered byeligible to participate in the principalstudy.
The investigatorfirst and10 con [...] [...]
2022-09-19
minor
2 amendments v20-v21
2 re-verifications since 2022-03-16, no change to tracked fields
2022-02-23
notable
Suspended→Recruiting Study Status, Contacts/Locations v19
Trial statusSuspended→Recruiting
Reason stoppedUnacceptable Toxicity→not stated
Study sitesdetails revised at 1 of 1 site
2021-12-16
notable
Recruiting→Suspended Study Status, Contacts/Locations v18
Trial statusRecruiting→Suspended
Reason stoppednot stated→Unacceptable Toxicity
Study sitesdetails revised at 1 of 1 site
2021-09-29
minor
Study Status, Eligibility v17
Eligibility criteria+1 characters
[...] capacity of the lung for carbon monoxide (DLCO) corrected >= 70% mm Hg
DLCO corrected between 60% - 69% mm Hg and partia [...]
2021-09-02
minor
Study Status, Outcome Measures, Eligibility v16
Eligibility criteria+90 characters
[...] Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Subjects must be >= 6 months old
Karnofsky >= 70 or Eastern Cooperative Oncology Group (ECOG) [...] rate, patients will be screened for anti-DSA pre-transplant,.
Patients andwith in case of positivity, the donorDSA will be excludedreviewed by the principal investigator and considered for desensitization treatment.
Secondary endpoints6 to 8 entries
Overall survival
Cumulative incidence of relapse
2021-07-23
minor
2 amendments v14-v15
2 re-verifications since 2021-05-18, no change to tracked fields
2021-03-18
minor
Study Identification, Study Status, Sponsor/Collaborators, Arms and Interventions, Eligibility v13
Eligibility criteria-91 characters
[...] compatibility
Major ABO incompatibility
Exclusion Criteria:
Patients with evidence of liver synthetic dysfunction or severe cirrhosis will be excluded
Active, uncontrolled, life-threatening viral, bacterial or f [...]
Collaborators1 entry, revised
Nationalmedac Cancer Institute (NCI)GmbH
2021-02-03
minor
Study Status v12
Start dateestimated 2021-02-11→confirmed 2021-01-25
2021-01-11
minor
Study Status v11
Start date2021-01-09→2021-02-11
2020-12-09
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v10
Trial statusNot Yet Recruiting→Recruiting
Start date2020-12-16→2021-01-09
Study sitesdetails revised at 1 of 1 site
2020-11-16
minor
Study Status v9
Start date2020-11-14→2020-12-16
2020-10-14
minor
Study Status, Study Description, Conditions, Arms and Interventions, Eligibility v8
Start date2020-10-03→2020-11-14
Eligibility criteriarevised
[...] ogeneic hematopoietic cell transplant are eligible, but the firstprior transplant must have been performed at least 63 months prior to enrollment, unless in case of graft failure [...]
Study description+7 characters
[...] on day 5, patients receive cyclosporine IV twice daily (BID) or three times daily (TID) over 1-2 hours or orally (PO) (after 3 months, in the abse [...] ing on day 5, patients also receive mycophenolate sodium PO three times daily (TID) or mycophenolate mofetil IV or PO TID until day 35 (may be [...]
2020-09-23
minor
Study Status v7
Re-verified, no change to tracked fields
2020-09-08
minor
Study Status v6
Primary completion date2022-12-27→2023-12-31
Completion date2022-12-27→2025-12-31
2020-09-03
minor
Study Identification, Study Status v5
Start date2020-09-03→2020-10-03
2020-08-03
minor
Study Status v4
Start date2020-08-01→2020-09-03
2020-07-01
minor
Study Status v3
Start date2020-07-01→2020-08-01
2020-03-03
minor
Study Status v2
Start date2020-03-03→2020-07-01
2020-02-03
minor
Study Status v1
Start date2020-01-31→2020-03-03